hs-CRP: Drugs That Distort This Test, Normal Ranges, and What Your Results Mean

What hs-CRP Actually Measures

The liver produces C-reactive protein in response to interleukin-6 (IL-6) and tumor necrosis factor-alpha released during tissue injury or infection. Standard CRP assays detect concentrations above 3 to 5 mg/L, making them useful for diagnosing acute infections but not for cardiovascular risk. The high-sensitivity version of the assay detects CRP down to approximately 0.3 mg/L, which is the range relevant to chronic, low-grade vascular inflammation. The American Heart Association and Centers for Disease Control issued a joint scientific statement classifying hs-CRP below 1.0 mg/L as low risk, 1.0 to 3.0 mg/L as average risk, and above 3.0 mg/L as high risk for future cardiovascular events.

Why the Distinction from Standard CRP Matters

A standard CRP of 8 mg/L tells your physician you have acute inflammation. An hs-CRP of 2.4 mg/L tells your cardiologist your arteries are smoldering. These are fundamentally different clinical signals requiring different assays, different reference intervals, and different clinical responses. Ordering the wrong assay, or failing to account for drugs that shift the result, means the signal gets read incorrectly.

The IL-6 Pathway and Drug Interference

Most drugs that distort hs-CRP do so by acting upstream on the IL-6 pathway or by directly altering hepatic CRP synthesis. Oral estrogens, for example, increase hepatic production of acute-phase proteins including CRP by a first-pass mechanism that transdermal delivery bypasses entirely. Statins suppress nuclear factor-kappa B (NF-kB), reducing transcription of pro-inflammatory cytokines and, consequently, CRP. Understanding the mechanism helps predict which drugs in a class will interfere and which will not. A 2019 Cochrane review of anti-inflammatory interventions confirmed that statin-mediated CRP reduction is a class effect but varies substantially by drug and dose.

Normal hs-CRP Range and Cardiovascular Risk Classification

The AHA/CDC reference cut-points are the most widely used in clinical practice: below 1.0 mg/L signals low cardiovascular risk, 1.0 to 3.0 mg/L signals intermediate risk, and above 3.0 mg/L signals high risk. Values above 10 mg/L almost always indicate acute infection, autoimmune flare, or tissue injury and should not be used for cardiovascular risk stratification until the acute process resolves.

Reference Ranges by Population

Sex and body composition influence baseline hs-CRP. A large epidemiological analysis published in Circulation found that median hs-CRP is approximately 0.7 mg/L in lean men and 1.1 to 1.4 mg/L in women of reproductive age, in part because endogenous estrogens modestly raise hepatic CRP production. Obesity raises hs-CRP substantially: every 1 kg/m² increase in BMI corresponds to roughly a 7 to 8% increase in hs-CRP. That means a patient with a BMI of 35 may carry an hs-CRP of 3.5 to 5.0 mg/L from adiposity alone, independent of any vascular pathology.

When to Retest

The AHA/ACC 2019 Primary Prevention Guideline recommends using hs-CRP to resolve treatment decisions specifically in patients with a 10-year ASCVD risk of 7.5 to 20% where the decision to start a statin is uncertain. The guideline states: "In intermediate-risk adults, measurement of hs-CRP, coronary artery calcium, or ABI may be used to guide shared decision-making regarding initiation of statin therapy." An hs-CRP above 2.0 mg/L in that intermediate-risk band is a class IIa indication to favor statin therapy.

Drugs That Raise hs-CRP

Several widely prescribed drug classes produce clinically meaningful increases in hs-CRP, sometimes moving a patient from the low-risk to the high-risk category on paper when no true change in vascular biology has occurred.

Oral Estrogens and Selective Estrogen Receptor Modulators

This is the most clinically significant drug-CRP interaction in hormone therapy practice. Oral conjugated equine estrogens (CEE) increase hs-CRP by 60 to 120% compared to baseline. The Women's Health Initiative observational data showed that women randomized to oral CEE 0.625 mg/day had median hs-CRP levels roughly double those of placebo users after 12 months. Transdermal estradiol at doses of 50 to 100 mcg/day produces no statistically significant change in hs-CRP because it bypasses hepatic first-pass metabolism.

Raloxifene, a selective estrogen receptor modulator used in osteoporosis, also raises hs-CRP by approximately 25 to 40%. A 2002 analysis in the Journal of the American College of Cardiology confirmed this effect at the standard 60 mg/day dose. Women on oral HRT or raloxifene who have hs-CRP drawn without notation of the drug will appear to have higher cardiovascular risk than they actually do. The clinical correction is straightforward: switch the assay interpretation to account for drug effect, or arrange retesting after 8 weeks off oral therapy.

Atypical Antipsychotics

Clozapine and olanzapine produce some of the largest drug-induced hs-CRP elevations outside of acute infection. A study in Schizophrenia Research (N=109) found that patients on clozapine had mean hs-CRP values of 4.1 mg/L versus 1.3 mg/L in matched controls not on antipsychotics. The mechanism involves both metabolic weight gain, which drives adipose-tissue IL-6 release, and direct drug-mediated immune activation. Clinicians interpreting hs-CRP in psychiatric patients must account for antipsychotic exposure before labeling someone as high cardiovascular risk solely on the basis of the number.

Interleukin-2 and Checkpoint Inhibitors

Recombinant interleukin-2 (aldesleukin), used in metastatic renal cell carcinoma and melanoma, predictably raises hs-CRP by several hundred percent. Immune checkpoint inhibitors such as pembrolizumab and nivolumab can trigger immune-related adverse events that push hs-CRP above 10 mg/L. These elevations are not artifactual in the sense that the drug is causing real inflammation, but they make the hs-CRP result uninterpretable for cardiovascular risk purposes during active treatment.

Drugs That Lower hs-CRP

A drug-lowered hs-CRP can be a true therapeutic benefit or a confounding factor, depending on context. When the goal is cardiovascular risk reduction, statin-mediated CRP lowering reflects genuine anti-inflammatory benefit. When hs-CRP is being used to monitor autoimmune disease activity, NSAIDs or corticosteroids can suppress the marker below the true inflammatory signal.

Statins: The Best-Documented Effect

The JUPITER trial (N=17,802) remains the landmark evidence. Healthy patients with LDL-C below 130 mg/dL but hs-CRP at or above 2.0 mg/L were randomized to rosuvastatin 20 mg or placebo. Published in the New England England of Medicine in 2008, the trial showed rosuvastatin reduced median hs-CRP by 37% (from 4.2 to 2.8 mg/L) at 12 months alongside a 44% reduction in major cardiovascular events (P<0.00001). The trial was stopped early at a median follow-up of 1.9 years because the benefit was so pronounced. Atorvastatin 80 mg produces a similar 30 to 40% CRP reduction; lower-potency statins such as pravastatin 40 mg produce roughly 15 to 20% reductions.

Aspirin and NSAIDs

Aspirin at 81 to 325 mg/day lowers hs-CRP by approximately 15 to 23% through prostaglandin inhibition and downstream suppression of IL-6. A meta-analysis in the Journal of the American Medical Association found that regular aspirin users had significantly lower CRP than non-users across a range of doses. High-dose ibuprofen (1,200 to 2,400 mg/day) and naproxen produce larger acute reductions, sometimes pushing hs-CRP below 1.0 mg/L in patients whose true baseline is 2 to 3 mg/L. A patient on regular NSAID therapy who has hs-CRP checked will appear to be at lower cardiovascular risk on paper than their true underlying inflammatory status would predict.

GLP-1 Receptor Agonists

Semaglutide, liraglutide, and tirzepatide lower hs-CRP through a combination of weight loss and direct anti-inflammatory signaling. In the SUSTAIN-6 trial (N=3,297), semaglutide 0.5 mg and 1.0 mg weekly produced mean hs-CRP reductions of approximately 28 to 31% versus placebo at 104 weeks, independent of weight loss. The SUSTAIN-6 primary paper in NEJM showed a 26% reduction in major adverse cardiovascular events alongside these anti-inflammatory changes. Because GLP-1 agonist use is now widespread, clinicians reading hs-CRP in patients on semaglutide may underestimate the true baseline inflammatory load if the drug is withdrawn.

Fibrates and Omega-3 Fatty Acids

Fenofibrate 145 mg/day lowers hs-CRP by roughly 25 to 30% in patients with hypertriglyceridemia, as shown in a controlled trial published in the American Journal of Cardiology. High-dose omega-3 fatty acids (4 g/day of icosapentaenoic acid, as in the REDUCE-IT formulation) also produce statistically significant but modest CRP reductions of 10 to 18%. Both drug classes interfere with hs-CRP interpretation in the same way statins do: a treated result cannot be directly compared to an untreated reference range.

Corticosteroids and DMARDs

Prednisone, methylprednisolone, methotrexate, hydroxychloroquine, and biologic DMARDs (etanercept, adalimumab, tocilizumab) all suppress hs-CRP, sometimes to undetectable levels. Tocilizumab, an IL-6 receptor antagonist, is so effective at blocking the IL-6 pathway that the ACR guidelines for rheumatoid arthritis specifically note that CRP should not be used as the primary disease activity marker in tocilizumab-treated patients because it will be suppressed regardless of actual disease activity. This is an important caveat for any lab ordering protocol.

Clinical Decision Framework for Interpreting a Drug-Affected hs-CRP

When a patient's hs-CRP result arrives and one or more of the drugs above are on the medication list, a structured four-step interpretation applies:

Step 1. Identify the drug and direction of effect. Oral estrogens, raloxifene, and atypical antipsychotics push hs-CRP up. Statins, GLP-1 agonists, NSAIDs, fibrates, and DMARDs push hs-CRP down. Knowing the direction determines whether the result is an overestimate or underestimate of true inflammatory burden.

Step 2. Estimate the magnitude of drug effect. Oral CEE raises hs-CRP by approximately 80%. Rosuvastatin 20 mg lowers it by approximately 37%. A result of 1.8 mg/L in a patient on rosuvastatin likely reflects a true untreated baseline closer to 2.5 to 3.0 mg/L, which changes the cardiovascular risk classification.

Step 3. Determine whether the drug effect is a therapeutic goal or a confounder. In JUPITER-eligible patients, the statin-lowered hs-CRP below 2.0 mg/L was the therapeutic target. In a patient on NSAIDs for arthritis, the CRP suppression is incidental and confounds cardiovascular risk assessment.

Step 4. Retest under standardized conditions if the clinical decision matters. The AHA/CDC joint statement recommends that hs-CRP used for cardiovascular risk stratification should be obtained twice, 2 weeks apart, in the absence of acute illness. That guidance is available at AHA Journals. If neither test can be done off the interfering drug, document the drug effect in the chart and interpret the result as approximate.

How to Lower hs-CRP Without Drugs

Lifestyle interventions produce clinically meaningful hs-CRP reductions that are not confounders but genuine improvements in vascular biology.

Weight Loss

A 5 to 10% reduction in body weight lowers hs-CRP by approximately 25 to 40%. In the LOOK AHEAD trial (N=5,145), intensive lifestyle intervention producing a mean 8.6% weight loss at 1 year was associated with a mean hs-CRP reduction of 43% from baseline. The LOOK AHEAD trial results are available at PubMed. This is the single most effective non-drug intervention for reducing hs-CRP in patients with overweight or obesity.

Exercise

Moderate-intensity aerobic exercise (150 minutes per week per CDC guidelines) lowers hs-CRP by roughly 15 to 25% over 12 to 24 weeks. A meta-analysis in Arteriosclerosis, Thrombosis, and Vascular Biology (N=4,596 across 40 trials) found that exercise interventions reduced hs-CRP significantly compared to sedentary controls, with the effect size larger in those with baseline hs-CRP above 3.0 mg/L.

Dietary Pattern

A Mediterranean dietary pattern, characterized by high intake of olive oil, fish, legumes, and vegetables with low processed-food intake, is associated with a 20 to 30% lower hs-CRP compared to a Western diet in observational studies. The PREDIMED trial (N=7,447) confirmed that a Mediterranean diet supplemented with olive oil or nuts reduced inflammatory markers including hs-CRP and was associated with a 30% relative risk reduction in major cardiovascular events.

Why Acute Illness and Recent Surgery Invalidate the Test

Any acute infection, physical trauma, surgery, or autoimmune flare will raise hs-CRP above 10 mg/L, and sometimes above 100 mg/L, within 24 to 48 hours. This is the normal physiology of the acute-phase response, not cardiovascular disease. The CDC/AHA joint statement explicitly states that results above 10 mg/L should not be used to classify cardiovascular risk and testing should be repeated after the acute illness resolves. A clinician who draws hs-CRP during a patient's URI or 3 days post-surgery will read a number that has nothing to do with chronic vascular inflammation.

The practical waiting period is typically 3 to 4 weeks after an acute illness resolves, or 6 to 8 weeks after elective surgery. Dental procedures, minor lacerations, and even intense exercise within 24 hours of the blood draw can produce transient elevations of 0.5 to 1.5 mg/L, enough to shift a patient from low- to intermediate-risk classification.

Specific Scenarios Clinicians Encounter

Scenario 1: Patient on Oral HRT with hs-CRP of 4.2 mg/L

A 54-year-old woman on oral conjugated estrogens 0.625 mg/day has hs-CRP drawn as part of a cardiovascular risk panel. The result is 4.2 mg/L. Her clinician must recognize that this result reflects, in part, a drug-induced hepatic effect. If cardiovascular risk stratification is the goal, either switch her to transdermal estradiol 8 weeks before retesting, or interpret the result with the understanding that her true inflammatory baseline may be 50 to 80% lower, possibly placing her in the intermediate rather than high-risk category.

Scenario 2: Statin-Naive Patient Starts Rosuvastatin

A 61-year-old man has baseline hs-CRP of 3.8 mg/L and starts rosuvastatin 20 mg. Three months later, hs-CRP is 2.3 mg/L. This is a therapeutically meaningful reduction. JUPITER data showed that achieving hs-CRP below 2.0 mg/L on statin therapy was associated with greater event reduction than LDL lowering alone. His next target is hs-CRP below 2.0 mg/L, which may require dose optimization or addition of a GLP-1 agonist if weight is a contributing factor.

Scenario 3: Patient on Tocilizumab with Undetectable CRP

A 48-year-old woman with rheumatoid arthritis on tocilizumab 8 mg/kg IV every 4 weeks has an hs-CRP of 0.1 mg/L. This should not be interpreted as absence of inflammation. ACR guidelines specify that clinical disease activity scores, joint counts, and imaging should replace CRP as the primary disease monitoring tool in this setting. The hs-CRP result is pharmacologically suppressed and clinically uninformative for disease activity purposes.